Zentalis Pharmaceuticals (NASDAQ:ZNTL) Upgraded by Wall Street Zen to “Sell” Rating

Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued on Sunday.

Several other analysts also recently issued reports on ZNTL. Wells Fargo & Company began coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target for the company. Guggenheim boosted their price target on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.83.

Zentalis Pharmaceuticals Trading Down 1.2%

ZNTL stock opened at $4.00 on Friday. The firm has a market capitalization of $284.76 million, a PE ratio of -2.31 and a beta of 1.99. Zentalis Pharmaceuticals has a 1-year low of $1.13 and a 1-year high of $6.95. The business’s 50 day simple moving average is $3.75 and its 200 day simple moving average is $2.67.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). As a group, sell-side analysts predict that Zentalis Pharmaceuticals will post -1.93 EPS for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. 5AM Venture Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 705.7% during the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock worth $5,330,000 after buying an additional 3,457,913 shares during the last quarter. Millennium Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 220.6% during the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after buying an additional 2,111,951 shares during the last quarter. Ishara Investments LP bought a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter worth $1,782,000. Opaleye Management Inc. lifted its position in shares of Zentalis Pharmaceuticals by 342.6% during the 4th quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock worth $1,891,000 after buying an additional 1,084,356 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth $1,126,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.